<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>AMMONIUM MOLYBDATEÂ - ammonium molybdateÂ injection, solutionÂ </strong><br>American Regent, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1><span class="Bold">AMMONIUM MOLYBDATE INJECTION, USP</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">STERILE, NONPYROGENIC</span></p>
<p><span class="Bold">TRACE ELEMENT ADDITIVE</span></p>
<p><span class="Bold">FOR IV USE AFTER DILUTION</span></p>
<p><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION
</span></h1>
<p class="First">Ammonium Molybdate Injection, USP is a sterile, nonpyrogenic solution for use as an additive to solutions for Total Parenteral Nutrition (TPN). Each mL contains Ammonium Molybdate Tetrahydrate (NH<span class="Sub">4</span>)<span class="Sub">6</span>MO<span class="Sub">7</span>O<span class="Sub">24</span>â€¢4H<span class="Sub">2</span>O, 46 mcg and Water for Injection q.s. Each mL provides 25 mcg of Molybdenum. Ammonium Hydroxide and/or Hydrochloric Acid may have been added to adjust pH.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<p class="First">Molybdenum is a constituent of the enzymes xanthine oxidase, sulfite oxidase, and aldehyde oxidase. Among other reactions, xanthine oxidase catalyzes conversion of xanthine and hypoxanthine to uric acid; sulfite oxidase converts sulfite to sulfate; and aldehyde oxidase detoxifies a variety of harmful organic molecules (such as aldehydes into acids).</p>
<p>In humans, molybdenum deficiency resulting from prolonged TPN support has been reported in literature. The deficiency syndrome included <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">night blindness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, central <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotomas</span>, culminating in <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. The biochemical changes associated with the syndrome were: <span class="product-label-link" type="condition" conceptid="4182278" conceptname="Hypermethioninemia">hypermethioninemia</span>, hypouricemia, hypouricosuria, low urinary excretion of inorganic sulfate and elevated urinary excretion of Thiosulfate. Supplementation of TPN solutions with Molybdenum has been reported to alleviate the symptoms and normalize the biochemical abnormalities.</p>
<p>In animals, diet induced molybdenum deficiency has been produced experimentally with tungstate. The deficiency symptoms are characterized by decreased <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, food consumption, and life expectancy and deranged microbiological processes in the rumen. Renal xanthine calculi have been reported in sheep grazing on low-molybdenum pasture.</p>
<p>Tissue storage of molybdenum varies with the intake levels and are affected by the amount of copper and sulfate in the diet. Consistent levels are observed in liver, kidney, and adrenal cortex.</p>
<p>Molybdenum is primarily excreted via kidneys. Some excretion through bile also occurs.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<p class="First">Ammonium Molybdate Injection, USP is indicated for use as a supplement to TPN solutions. Administration of Molybdenum in TPN solutions helps to prevent depletion of endogenous stores and subsequent deficiency symptoms.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<ol class="Arabic">
<li>Ammonium Molybdate Injection, USP should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>.</li>
<li>Ammonium Molybdate Injection, USP without copper supplementation should not be given to copper-deficient patients.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS
</span></h1>
<ol class="Arabic">
<li>Molybdenum has been reported to promote the mobilization of tissue copper, and increase urinary excretion of copper both in humans and animals. Excessive amounts of Molybdenum can therefore produce <span class="product-label-link" type="condition" conceptid="4024266" conceptname="Hypocupremia">copper deficiency</span>. The metabolism of copper in patients receiving Molybdenum supplements in TPN solution should be frequently checked.</li>
<li>Purine and sulfur metabolic profiles should be frequently carried out in patients receiving molybdenum supplements in TPN solutions.</li>
<li>Ammonium Molybdate Injection, USP is a hypotonic solution and should be administered in admixtures only.</li>
</ol>
<p class="First">This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.</p>
<p>Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<p class="First">As molybdenum is excreted in urine and bile, Molybdenum supplements may need to be adjusted, reduced, or omitted in renal dysfunction and <span class="product-label-link" type="condition" conceptid="201066" conceptname="Obstruction of bile duct">bile duct obstruction</span>.</p>
<p>Molybdenum metabolism has been reported to be inversely related to copper, sulfate ions, tungsten, methionine, and cysteine.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold Italics">Pregnancy
</span></h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.1.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects
</span></h3>
<p class="First"><span class="Bold Italics">Pregnancy Category C</span></p>
<p>Animal reproduction studies have not been conducted with Ammonium Molybdate Injection, USP. It is also not known whether Ammonium Molybdate Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Ammonium Molybdate Injection, USP should be given to a pregnant woman only if clearly needed. Molybdenum has been reported to cross placenta. Molybdenum has also been detected in cow and sheep milk.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<p class="First">The amount of molybdenum in Ammonium Molybdate Injection, USP is small and toxicity symptoms are unlikely to occur at the recommended dosage level.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<p class="First">In humans, consumption of food grown in molybdeniferous soils, estimated to provide 10 to 15 mg molybdenum/day, has been associated with goutlike syndrome with increased blood levels of molybdenum, uric acid, and xanthine oxidase.</p>
<p>In animals, cattle grazing on molybdeniferous pasture have been reported to develop molybdenosis known as â€œteartâ€? or â€œpeat scoursâ€?. The condition is characterized by <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, bone deformities, growth failure, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Similar conditions except <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, have been experimentally induced in rat, chicken, and sheep maintained on high dietary Molybdenum intakes.</p>
<p>No information on the treatment of molybdenosis in humans is available. Among animals, treatment with copper, sulfate ions, and tungsten has been reported to enhance excretion of molybdenum thus imparting protection against molybdenosis. The sulfur-containing amino acids, methionine and cysteine, have also been reported to afford limited protection in molybdenosis in sheep.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First">Ammonium Molybdate Injection, USP provides 25 mcg molybdenum/mL. For metabolically stable adults receiving TPN, the suggested additive dosage level is 20 to 120 mcg molybdenum/day. For pediatric patients, the additive dosage level should be calculated by extrapolation.</p>
<p>In an adult, molybdenum deficiency state resulting from prolonged TPN support, intravenous administration of molybdenum as ammonium molybdate at 163 mcg/day for 21 days has been reported to reverse deficiency symptoms without toxicity.</p>
<p>Aseptic addition of Ammonium Molybdate Injection, USP to TPN solutions under a laminar flow hood is recommended. Molybdenum is physically compatible with the electrolytes and other trace elements usually present in amino acid/dextrose solutions used for TPN. Monitoring of sulfur and purine metabolism is suggested as a guideline. Since copper and molybdenum are antagonistic to each other, frequent monitoring of blood copper levels should be carried out during molybdenum TPN supplementation.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED
</span></h1>
<p class="First">Ammonium Molybdate Injection, USP (molybdenum 25 mcg/mL)</p>
<p>NDC 0517-6610-25Â Â Â Â Â Â Â Â Â Â  10 mL Single Dose VialÂ Â Â Â Â Â Â Â Â Â  packed in boxes of 25</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) (See USP Controlled Room Temperature).</p>
<p>AMERICAN REGENT, INC.<br>SHIRLEY, NY 11967</p>
<p>IN6610</p>
<p>Rev. 1/09</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<p class="First">PRINCIPAL DISPLAY PANEL â€“ 10 mL Carton</p>
<p><span class="Bold">AMMONIUM MOLYBDATE</span><br>INJECTION, USP</p>
<p><span class="Bold">Molybdenum 250 mcg/10 mL</span></p>
<p><span class="Bold">(25 mcg/mL)</span></p>
<p>Trace Element Additive</p>
<p><span class="Bold">NDC 0517-6610-25</span></p>
<p><span class="Bold">25 x 10 mL SINGLE DOSE VIALS</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE AFTER DILUTION</span></p>
<p><span class="Bold">PRESERVATIVE FREE</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Each mL contains: Ammonium Molybdate (Tetrahydrate) 46 mcg, Water for Injection q.s.<br>pH adjusted with Ammonium Hydroxide and/or Hydrochloric Acid. Sterile, nonpyrogenic.</p>
<p><span class="Bold">WARNING:</span> DISCARD UNUSED PORTION. Store at 20Â°-25Â°C (68Â°-77Â°F); excursions permitted to 15Â°-30Â°C (59Â°-86Â°F) (See USP Controlled Room Temperature).</p>
<p>Directions for Use: See Package Insert.</p>
<p><span class="Bold">AMERICAN</span><span class="Bold"><br></span><span class="Bold">REGENT, INC.</span></p>
<p>SHIRLEY, NY 11967</p>
<p>Rev. 11/05</p>
<div class="Figure"><img alt="18d83044-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43558add-4c7e-4fe6-ad36-cdceaff99bfb&amp;name=18d83044-figure-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMMONIUM MOLYBDATEÂ 		
					</strong><br><span class="contentTableReg">ammonium molybdate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0517-6610</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMMONIUM MOLYBDATE</strong> (MOLYBDENUM) </td>
<td class="formItem">AMMONIUM MOLYBDATE</td>
<td class="formItem">46Â ug Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0517-6610-25</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">09/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>American Regent, Inc.
							(622781813)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>18d83044-4b09-45be-a6c4-00f4e6d3d3fb</div>
<div>Set id: 43558add-4c7e-4fe6-ad36-cdceaff99bfb</div>
<div>Version: 1</div>
<div>Effective Time: 20111007</div>
</div>
</div>Â <div class="DistributorName">American Regent, Inc.</div></p>
</body></html>
